Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
Hong Kong ECM continues its win streak. New Horizon Health (6606 HK) closed 3x of its IPO on its debut on Thursday. And the timing and conditions couldn't be any better for investors to start looking at a potential selldown of Tencent Holdings (700 HK) block by Prosus NV (PRX SJ) as its three-year lock-up period comes close to expiry. Sumeet Singh shared his analysis on why a selldown is likely to come soon and how one should position leading up to the selldown.
For upcoming IPOs, Sciclone Pharmaceuticals (6600 HK) and Joinn Laboratories (H) (6127 HK) launched their bookbuilds to raise up to US$281m and US$843m, respectively. Ke Yan, CFA, FRM shared his thoughts on deals in:
Cheerwin (CHEER HK) won approval for its Hong Kong IPO and has been premarketing this week. Books will likely open soon (likely this coming week). We also covered of other upcoming IPOs such as Bairong (1569395D CH), Betta Pharmaceuticals (300558 CH) (A+H), Intco Medical Technology Co., Ltd-A (300677 CH), and most importantly, our first look at JD Logistics (JDL HK).
In the U.S, Coupang (CPNG US) filed its prospectus last week and bookbuild will likely be launched soon. We looked at the good and bad of the company and the competitive landscape that it operates in.
Singapore IPO market is also looking good this year with Aztech (AZ SP) likely to launch its books very soon (next week) and Thai Beverage (THBEV SP) confirming its plans to spin out BeerCo.
In India, Brookfield India Real Estate Trust (1862893D IN) raised about US$520m in its IPO. Share price didn't hold up well likely due to issues regarding the quality of assets.
Placements:
Our overall accuracy rate is 73.9% for IPOs and 67.2% for Placements
(Performance measurement criteria is explained at the end of the note)
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.